The stock has a 36-month beta value of 0.84. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IDYA is 75.07M, and at present, short sellers hold a 15.85% of that float. On July 31, 2024, the average trading volume of IDYA was 1.01M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IDYA) stock’s latest price update
Ideaya Biosciences Inc (NASDAQ: IDYA)’s stock price has soared by 0.16 in relation to previous closing price of 42.25. Nevertheless, the company has seen a gain of 0.25% in its stock price over the last five trading days. prnewswire.com reported 2024-07-31 that Option for an exclusive worldwide license for potential first-in class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program B7H3/PTK7 co-expression found in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancers Rational combo opportunities with IDEAYA’s DNA Damage Repair (DDR) pipeline, including IDE161 (PARG) Targeting development candidate nomination in H2 2024 SOUTH SAN FRANCISCO, Calif. and BEIJING, China , July 31, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an option and license agreement for a potential first-in-class B7H3/PTK7 BsADC program with Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
IDYA’s Market Performance
Ideaya Biosciences Inc (IDYA) has seen a 0.25% rise in stock performance for the week, with a 17.81% gain in the past month and a 4.10% surge in the past quarter. The volatility ratio for the week is 3.60%, and the volatility levels for the past 30 days are at 5.21% for IDYA. The simple moving average for the past 20 days is 5.78% for IDYA’s stock, with a 11.03% simple moving average for the past 200 days.
Analysts’ Opinion of IDYA
Many brokerage firms have already submitted their reports for IDYA stocks, with Mizuho repeating the rating for IDYA by listing it as a “Outperform.” The predicted price for IDYA in the upcoming period, according to Mizuho is $50 based on the research report published on July 08, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see IDYA reach a price target of $55. The rating they have provided for IDYA stocks is “Buy” according to the report published on March 08th, 2024.
SVB Securities gave a rating of “Outperform” to IDYA, setting the target price at $33 in the report published on August 08th of the previous year.
IDYA Trading at 9.41% from the 50-Day Moving Average
After a stumble in the market that brought IDYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.35% of loss for the given period.
Volatility was left at 5.21%, however, over the last 30 days, the volatility rate increased by 3.60%, as shares surge +25.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.44% upper at present.
During the last 5 trading sessions, IDYA rose by +0.21%, which changed the moving average for the period of 200-days by +54.95% in comparison to the 20-day moving average, which settled at $40.43. In addition, Ideaya Biosciences Inc saw 18.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IDYA starting from WHITE MICHAEL ANTHONY, who sale 28,500 shares at the price of $36.24 back on May 29 ’24. After this action, WHITE MICHAEL ANTHONY now owns 0 shares of Ideaya Biosciences Inc, valued at $1,032,884 using the latest closing price.
Hata Yujiro S, the President and CEO of Ideaya Biosciences Inc, sale 34,433 shares at $41.81 during a trade that took place back on May 16 ’24, which means that Hata Yujiro S is holding 677,887 shares at $1,439,754 based on the most recent closing price.
Stock Fundamentals for IDYA
Current profitability levels for the company are sitting at:
- -10.27 for the present operating margin
- 0.74 for the gross margin
The net margin for Ideaya Biosciences Inc stands at -8.31. The total capital return value is set at -0.17. Equity return is now at value -20.31, with -19.44 for asset returns.
Based on Ideaya Biosciences Inc (IDYA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -54.51. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -6.35.
Currently, EBITDA for the company is -130.42 million with net debt to EBITDA at 0.67. When we switch over and look at the enterprise to sales, we see a ratio of 222.75. The receivables turnover for the company is 1033.67for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 28.42.
Conclusion
To sum up, Ideaya Biosciences Inc (IDYA) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
